Novo Nordisk stock news
On July 24, 2026, a U.S. FDA advisory committee recommended easing compounding restrictions on several peptides, a development that could intensify market competition for Novo Nordisk's GLP--1 franchise by facilitating broader access to compounded alternatives. This regulatory shift has prompted analysts to scrutinize the company's "easy growth" trajectory, although current valuation models from Simply Wall St indicate that NVO shares may still be undervalued by approximately 21.5% relative to their intrinsic fair value.